{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:28:54Z","timestamp":1792412934925,"version":"4.4.0"},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Methotrexate (MTX) is the anchor drug for the treatment of rheumatoid arthritis (RA). MTX is associated with adverse events that limit its use. The MTX intolerance severity score (MISS) was developed to identify symptoms related to MTX use in juvenile idiopathic arthritis and RA patients. The aim of this study is to translate and validate the MISS in the Arabic language.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forward and backward translation of the MISS were performed by two fluent Arabic translators and reviewed by three rheumatologists. Consecutive patients with RA who used MTX for \u22653\u00a0months were recruited from two tertiary care centers in Riyadh, Saudi Arabia. A test was considered positive if the patient scored \u22656 points. The internal consistency and stability of the items were evaluated using Cronbach's alpha and the test\u2010retest method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 185 patients were recruited. Of those patients, 158 (85.4%) were female. The mean (\u00b1SD) age and disease duration were 49.7 (\u00b112.67) and 8.67 (\u00b17.1)\u00a0years, respectively. The mean Disease Activity Score of 28 joints was 3.2 (\u00b11.3). Fifty\u2010five (30%) patients were illiterate. Seventy\u2010three (39.5%) patients had a positive MISS. Of those patients, 55 (75.3%) and 18 (24.7%) were using the oral and subcutaneous forms of MTX, respectively. The Arabic MISS had good internal consistency (Cronbach's alpha\u00a0=\u00a00.792) and a factorable study size for test\u2010retest and factor analysis (Kaiser\u2010Meyer\u2010Olkin\u00a0=\u00a00.745).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The Arabic MISS showed validity and good reliability in detecting MTX intolerance in RA patients. MTX intolerance is prevalent among RA patients. Larger studies are needed to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13637","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T11:36:16Z","timestamp":1561635376000},"page":"1572-1577","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence of methotrexate intolerance among patients with rheumatoid arthritis using the Arabic version of the methotrexate intolerance severity score"],"prefix":"10.1111","volume":"22","author":[{"given":"Jawza","family":"Albaqami","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy King Saud University Riyadh Saudi Arabia"},{"name":"Department of Clinical Pharmacy Security Force Hospital Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Alshalhoub","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy King Saud University Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Almalag","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy King Saud University Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Dessougi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine Security Forces Hospital Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Al Harthi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine Security Forces Hospital Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed K.","family":"Bedaiwi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, College of Medicine King Saud University Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9373-5473","authenticated-orcid":false,"given":"Mohammed A.","family":"Omair","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, College of Medicine King Saud University Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"issue":"71","key":"e_1_2_6_2_1","first-page":"S9","article-title":"Update on methotrexate as the anchor drug for rheumatoid arthritis","volume":"2013","author":"Pincus T","year":"2013","journal-title":"Bull Hosp Jt Dis"},{"issue":"3","key":"e_1_2_6_3_1","first-page":"480","article-title":"Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study","volume":"25","author":"Meer A","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000173616.81928.44"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30367"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3243-8"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4413"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-319X(03)00004-6"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200012150-00014"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39480"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12735"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-017-0754-1"},{"key":"e_1_2_6_16_1","first-page":"CD010227","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti\u2010rheumatic drugs for rheumatoid arthritis: A network meta\u2010analysis","volume":"8","author":"Hazlewood GS","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"e_1_2_6_17_1","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta\u2010analysis of drug registries and health care databases","volume":"55","author":"Souto A","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2012.05.004"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.06.054"},{"issue":"5","key":"e_1_2_6_20_1","first-page":"S68","article-title":"Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low\u2010dose methotrexate in information presented to physicians and patients","volume":"28","author":"Pincus T","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006918"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12183"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh587"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2246-8"},{"issue":"5","key":"e_1_2_6_25_1","first-page":"S95","article-title":"Side effects and management of side effects of methotrexate in rheumatoid arthritis","volume":"28","author":"Albrecht K","year":"2010","journal-title":"Clin Exp Rheumatol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13637","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T06:50:37Z","timestamp":1694328637000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/1756-185X.13637"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13637","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,27]]},"assertion":[{"value":"2018-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}